Spots Global Cancer Trial Database for darolutamide
Every month we try and update this database with for darolutamide cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| TT-702 in Patients With Advanced Solid Tumours. | NCT05272709 | Advanced Solid ... | TT-702 Darolutamide | 16 Years - | Cancer Research UK | |
| Treatment With Darolutamide +/- Radiation Therapy for Patients With a Castration Resistant Cancer and Metastases Detected by Functional Imaging | NCT06276465 | Prostatic Cance... | Darolutamide 30... Stereotactic bo... Androgen depriv... | 18 Years - | UNICANCER | |
| Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score | NCT05050084 | Prostate Adenoc... | Bicalutamide Buserelin Darolutamide Degarelix Flutamide Goserelin Histrelin Leuprolide Radiation Thera... Relugolix Triptorelin | 18 Years - | NRG Oncology | |
| A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Castration-Resistant Prostate Cancer | NCT05818683 | Metastatic Cast... | JNJ-78278343 Cetrelimab Cabazitaxel Docetaxel Apalutamide Enzalutamide Darolutamide Abiraterone ace... | 18 Years - | Janssen Research & Development, LLC | |
| Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA | NCT04319783 | Advanced Prosta... Cancer of Prost... PSA Castrate Resist... | Darolutamide Radiotherapy | 18 Years - | Trans Tasman Radiation Oncology Group | |
| Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide | NCT04335682 | Metastatic Pros... Prostate Cancer... Prostate Cancer Castrate Resist... | Darolutamide Enzalutamide | 18 Years - | Alliance Foundation Trials, LLC. | |
| A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC | NCT05849298 | Prostatic Neopl... | AAA617 AAA517 Piflufolastat F... ARPI ADT Best supportive... | 18 Years - | Novartis | |
| A Phase 2 Trial of Darolutamide as a Prostate-Specific Membrane Antigen (PSMA) Expression Enhancer in Patients With Localized Prostate Cancer | NCT05900973 | Prostate Cancer | Darolutamide Or... | 18 Years - | D'Or Institute for Research and Education | |
| Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate | NCT04136353 | Prostate Cancer | Darolutamide Placebo oral ta... Luteinizing Hor... External Beam R... | 18 Years - | University of Sydney | |
| A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC | NCT05849298 | Prostatic Neopl... | AAA617 AAA517 Piflufolastat F... ARPI ADT Best supportive... | 18 Years - | Novartis | |
| Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction | NCT04925648 | Metastatic Pros... | Dasatinib Darolutamide | 18 Years - | St Vincent's Hospital, Sydney | |
| A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies | NCT05794906 | Biochemically R... | Darolutamide (B... Placebo matchin... ADT | 18 Years - | Bayer | |
| A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer. | NCT05938270 | Prostate Cancer | Saruparib (AZD5... Darolutamide No Treatment | 18 Years - | AstraZeneca | |
| Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Study | NCT06430411 | Prostate Cancer... Prostate Cancer... Prostate Cancer Prostate Neopla... Oligometastatic... Oligometastasis | Radical prostat... Prostate irradi... Surgical metast... Irradiation of ... Abiraterone ace... Enzalutamide Darolutamide Apalutamide Docetaxel Lutetium-PSMA Androgen depriv... | 18 Years - 80 Years | Medical University of Vienna | |
| Evaluation of dAroLutamide Addition to anDrogen Deprivation Therapy and radIatioN Therapy in Newly Diagnosed Prostate Cancer With Pelvic Lymph Nodes Metastases | NCT05116475 | Prostate Cancer | Darolutamide 30... Placebo of Daro... | 18 Years - 120 Years | Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie | |
| Darolutamide With Radium-223 or Placebo and the Effect on Radiological Progression-Free Survival for Patients With mCSPC | NCT05771896 | Metastatic Pros... | Darolutamide Radium-223 | 18 Years - | GenesisCare USA | |
| Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer | NCT05617885 | Metastatic Pros... Non-metastatic ... Prostate Cancer | Darolutamide Abemaciclib GNRH-A Leuproli... GNRH-A Gosereli... Degarelix | 18 Years - | Dana-Farber Cancer Institute | |
| Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Study | NCT06430411 | Prostate Cancer... Prostate Cancer... Prostate Cancer Prostate Neopla... Oligometastatic... Oligometastasis | Radical prostat... Prostate irradi... Surgical metast... Irradiation of ... Abiraterone ace... Enzalutamide Darolutamide Apalutamide Docetaxel Lutetium-PSMA Androgen depriv... | 18 Years - 80 Years | Medical University of Vienna | |
| Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer | NCT05367440 | Metastatic Pros... | AZD5305 Enzalutamide Abiraterone Ace... Darolutamide Apalutamide | 18 Years - 130 Years | AstraZeneca | |
| Study on Androgen Receptor and Triple Negative Breast Cancer | NCT03383679 | Breast Cancer F... Triple Negative... | Darolutamide Capecitabine | 18 Years - | UNICANCER | |
| Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) | NCT06401980 | Metastatic Cast... | Darolutamide Standard of car... | 18 Years - | Swiss Group for Clinical Cancer Research | |
| Study of Radiation Therapy in Combination With Darolutamide + Degarelix in Intermediate Risk Prostate Cancer | NCT04176081 | Prostate Cancer | Darolutamide Degarelix Radiation Thera... | 18 Years - | University Health Network, Toronto | |
| Docetaxel or Cabazitaxel With or Without Darolutamide in mCRPC | NCT05762536 | Metastatic Cast... | Darolutamide Docetaxel or ca... | 18 Years - | Erasmus Medical Center | |
| Neoadjuvant Androgen Deprivation, Darolutamide, and Ipatasertib in Men With Localized, High Risk Prostate Cancer | NCT04737109 | Castrate Resist... | Ipatasertib Darolutamide Androgen Depriv... | 18 Years - | Big Ten Cancer Research Consortium | |
| A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer. | NCT05938270 | Prostate Cancer | Saruparib (AZD5... Darolutamide No Treatment | 18 Years - | AstraZeneca | |
| Stereotactic Body Radiotherapy With or Without Darolutamide for OligoRecurrent Prostate Cancer | NCT04641078 | Prostate Cancer Prostate Cancer... Prostate Cancer... Metastatic Canc... Oligometastasis | Darolutamide metastasis-dire... | 18 Years - | University Hospital, Ghent | |
| A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies | NCT05794906 | Biochemically R... | Darolutamide (B... Placebo matchin... ADT | 18 Years - | Bayer | |
| ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer | NCT03903835 | Metastatic Cast... Metastatic Horm... | Enzalutamide Or... Abiraterone Ora... Carboplatin Cabazitaxel 60 ... Docetaxel Injec... Radium Chloride... Niraparib plus ... Capivasertib pl... Apalutamide Darolutamide | 18 Years - | Karolinska Institutet | |
| Darolutamide With Radium-223 or Placebo and the Effect on Radiological Progression-Free Survival for Patients With mCSPC | NCT05771896 | Metastatic Pros... | Darolutamide Radium-223 | 18 Years - | GenesisCare USA | |
| Stereotactic Body Radiation Therapy Plus Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy for Treatment of Metastatic, Recurrent Hormone-Sensitive Prostate Cancer, DIVINE Trial | NCT06378866 | Recurrent Castr... Stage IVB Prost... Recurrent Prost... Castration-resi... | Abiraterone Apalutamide Biospecimen Col... Bone Scan Computed Tomogr... Darolutamide Degarelix Enzalutamide Goserelin Histrelin Leuprolide Magnetic Resona... Patient Observa... Positron Emissi... Prednisone Questionnaire A... Relugolix Stereotactic Bo... Triptorelin | 18 Years - | Mayo Clinic | |
| Study to Evaluate CCS1477 in Advanced Tumours | NCT03568656 | Metastatic Cast... Metastatic Brea... Non-small Cell ... Advanced Solid ... | CCS1477 Abiraterone ace... Enzalutamide Darolutamide Olaparib Atezolizumab | 18 Years - | CellCentric Ltd. | |
| Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer | NCT06173362 | Advanced Prosta... Stage III Prost... Stage IV Prosta... | Abiraterone Biospecimen Col... Darolutamide Prednisone | 18 Years - | University of California, Davis | |
| A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study. | NCT05059236 | Metastatic Horm... | Darolutamide (B... ADT | 18 Years - | Bayer | |
| Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer | NCT05367440 | Metastatic Pros... | AZD5305 Enzalutamide Abiraterone Ace... Darolutamide Apalutamide | 18 Years - 130 Years | AstraZeneca | |
| Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer | NCT06190899 | mCRPC (Metastat... Genital Disease... Urogenital Dise... Prostatic Disea... Prostatic Neopl... Prostate Cancer | Gedatolisib Darolutamide | 18 Years - | Celcuity Inc | |
| A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC Patients | NCT05676203 | Metastatic Horm... | Standard ADT (a... Standard Darolu... Docetaxel | 18 Years - | Jena University Hospital | |
| Study of Radiation Therapy in Combination With Darolutamide + Degarelix in Intermediate Risk Prostate Cancer | NCT04176081 | Prostate Cancer | Darolutamide Degarelix Radiation Thera... | 18 Years - | University Health Network, Toronto | |
| A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study. | NCT05059236 | Metastatic Horm... | Darolutamide (B... ADT | 18 Years - | Bayer | |
| SUrGery With or Without dARolutamide in High-risk and/or Locally Advanced Prostate Cancer | NCT05826509 | Prostate Cancer | Surgery alone Peri-operative ... | 18 Years - | Institut Claudius Regaud | |
| Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents | NCT06120491 | Metastatic Cast... | Saruparib Placebo Abiraterone Ace... Darolutamide Enzalutamide | 18 Years - 130 Years | AstraZeneca | |
| Study on Androgen Receptor and Triple Negative Breast Cancer | NCT03383679 | Breast Cancer F... Triple Negative... | Darolutamide Capecitabine | 18 Years - | UNICANCER | |
| Docetaxel or Cabazitaxel With or Without Darolutamide in mCRPC | NCT05762536 | Metastatic Cast... | Darolutamide Docetaxel or ca... | 18 Years - | Erasmus Medical Center | |
| Extreme Bipolar Androgen Therapy With Darolutamide and Testosterone Cypionate in Patients With Metastatic Castration-Resistant Prostate Cancer (ExBAT Trial) | NCT04558866 | Prostate Cancer | Testosterone Cy... Darolutamide | 18 Years - | Latin American Cooperative Oncology Group | |
| Evaluation of dAroLutamide Addition to anDrogen Deprivation Therapy and radIatioN Therapy in Newly Diagnosed Prostate Cancer With Pelvic Lymph Nodes Metastases | NCT05116475 | Prostate Cancer | Darolutamide 30... Placebo of Daro... | 18 Years - 120 Years | Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie | |
| A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC Patients | NCT05676203 | Metastatic Horm... | Standard ADT (a... Standard Darolu... Docetaxel | 18 Years - | Jena University Hospital | |
| Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study | NCT04484818 | Prostate Carcin... | Darolutamide Goserelin Aceta... Leuprolide Acet... Placebo Adminis... Quality-of-Life... Triptorelin | 18 Years - | Eastern Cooperative Oncology Group | |
| INTREPId (INTermediate Risk Erection PreservatIon Trial) | NCT04025372 | Prostate Cancer | Bicalutamide GnRH Agonist Radiation Thera... Darolutamide | 18 Years - | Dana-Farber Cancer Institute | |
| A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer. | NCT05938270 | Prostate Cancer | Saruparib (AZD5... Darolutamide No Treatment | 18 Years - | AstraZeneca |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
